Neurol. praxi. 2018;19(1):37-40 | DOI: 10.36290/neu.2018.076

Immunoadsorption in treating neurological diseases

MUDr. Jiří Pi»ha
Centrum myasthenia gravis při Neurologické klinice 1. LF UK a VFN Praha
MS centrum při Neurologickém oddělení KZ a.s. – Nemocnice Teplice, o. z., Teplice

In recent years, immunoadsorption has become an increasingly recognized alternative to therapeutic plasmapheresis used totreat neurological diseases, such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myastheniagravis, neuromyelitis optica and its spectrum disorders, multiple sclerosis, or autoimmune encephalitides. In contrast to therapeuticplasmapheresis that requires plasma exchange with albumin or fresh-frozen plasma, immunoadsorption is a technique allowingselective removal of humoral factors, primarily of pathological autoantibodies, with a high-affinity adsorbent. This therapeuticmethod has fewer adverse effects when compared with plasmapheresis. It can significantly improve the treatment and prognosisof patients with autoimmune neurological disorders.

Keywords: therapeutic plasma exchange, immunoadsorption, autoantibodies

Published: March 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pi»ha J. Immunoadsorption in treating neurological diseases. Neurol. praxi. 2018;19(1):37-40. doi: 10.36290/neu.2018.076.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Baggi F, Ubiali F, Nava S, Nessi V, Andreetta F, Rigamonti A, Maggi L, Mantegazza R, Antozzi C. Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients. J Neuroimmunol. 2008; 201-202: 104-10. Go to original source... Go to PubMed...
    2. Bonnan M, Valentino R, Debeugny S, Merle H, Fergé JL, Mehdaoui H, Cabre P. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2017. Go to original source...
    3. Blaha M, Pitha J, Blaha V, Lanska M, Maly J, Filip S, Brndiar M, Langrova H. Experience with extracorporeal elimination therapy in myasthenia gravis. Transfus Apher Sci. 2011; 45(3): 251-256. Go to original source... Go to PubMed...
    4. Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M, Sekiguchi K, Kokubun N, Ichikawa H, Wong AH, Yuki N. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016; 86(9): 800-807. Go to original source... Go to PubMed...
    5. Dogan Onugoren M, Golombeck KS, Bien C, Abu-Tair M, Brand M, Bulla-Hellwig M, Lohmann H, Münstermann D, Pavenstädt H, Thölking G, Valentin R, Wiendl H, Melzer N, Bien CG. Immunoadsorption therapy in autoimmune encephalitides. Neurol Neuroimmunol Neuroinflamm. 2016; 3(2): 121-125. Go to original source... Go to PubMed...
    6. Dorst J, Kunz M, Vintonyak O, Senel M, Rau D, Fathinia P, Hansel A, Endruhn S, Fangerau T, Taranu D, Gastl R, Jesse S, Schuster J, Ludolph AC. Tumani H. Immunoadsorption with Regenerating Columns in Treatment of Steroid-Refractory Relapse in Multiple Sclerosis and Optic Neuritis. J Mult Scler. 2016; 3: 178.
    7. Fassbender C, Klingel R, Köhler W. Immunoadsorption for autoimmune encephalitis. Atheroscler Suppl. 2017; 30: 257-263. Go to original source... Go to PubMed...
    8. Finsterer J, Derfler K. Immunoadsorption in multifocal motor neuropathy. J Immunother. 1999; 22(5): 441-442. Go to original source... Go to PubMed...
    9. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997; 41(6): 789-796. Go to original source... Go to PubMed...
    10. Galldiks N, Burghaus L, Dohmen C, Teschner S, Pollok M, Leebmann J, Frischmuth N, Hollinger P, Nazli N, Fassbender C, Klingel R, Benzing T, Fink GR, Haupt WF. Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. Eur Neurol 2011; 66: 183-189. Go to original source... Go to PubMed...
    11. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015; 14: 1023-1036. Go to original source... Go to PubMed...
    12. Giovannoni G. Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype. J Neurol Neurosurg Psychiatry. 2006; 77(9): 1001-1002. Go to original source... Go to PubMed...
    13. Hempel P, Heinig B, Jerosch C, Decius I, Karczewski P, Kassner U, Kunze R, Steinhagen-Thiessen E, Bimmler M. Immunoadsorption of agonistic autoantibodies against ?1-adrenergic receptors in patients with mild to moderate dementia. Ther Apher Dial. 2016; 20(5): 523-529. Go to original source... Go to PubMed...
    14. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014; 9: CD002063,dostupné z http://dx.doi.org/10.1002/14651858.CD002063.pub6. Go to original source... Go to PubMed...
    15. Karczewski P, Hempel P, Kunze R, Bimmler M. Agonistic autoantibodies to the ?(1) - adrenergic receptor and the ?(2) - adrenergic receptor in Alzheimer's and vascular dementia. Scand J Immunol. 2012; 75(5): 524-530. Go to original source... Go to PubMed...
    16. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; Neuromyelitis Optica Study Group. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016; 79(2): 206-216. Go to original source... Go to PubMed...
    17. Koziolek MJ, Kitze B, Mühlhausen J, Müller GA. Immunoadsorption in steroid-refractory multiple sclerosis. Atheroscler Suppl. 2013; 14(1): 175-178. Go to original source... Go to PubMed...
    18. Köhler W, Bucka C, Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 2011; 26: 347-355. Go to original source... Go to PubMed...
    19. Köhler W, Ehrlich S, Dohmen C, Haubitz M, Hoffmann F, Schmidt S, Klingel R, Kraft A, Neumann-Haefelin T, Topka H, Stich O, Baumgartner A, Fassbender C. Tryptophan immunoadsorption for the treatment of autoimmuneencephalitis. Eur J Neurol 2015;22:203-6. Go to original source... Go to PubMed...
    20. Krýsl D, Eliąák M. Autoimunitní encefalitidy. Cesk Slov Neurol N 2015; 78/ 111(1): 7-23. Go to original source...
    21. Levy RL, Newkirk R, Ochoa J. Treating chronic relapsing Guillain-Barré syndrome by plasma exchange. Lancet 1979; 2: 259-260. Go to original source... Go to PubMed...
    22. Lieker I, Slowinski T, Harms L, Hahn K, Klehmet J. A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy. J Clin Apher. 2017 May 9. Go to original source... Go to PubMed...
    23. Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, Taylor BV, Dyck PJ, Kiernan MC, Lin CS. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 2015; 86(9): 973-985. Go to original source... Go to PubMed...
    24. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1 clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-516. Go to original source... Go to PubMed...
    25. Mörtzell Henriksson M, Newman E, Witt V, Derfler K, Leitner G, Eloot AS, Dhondt A, Deeren D, Rock G, Ptak J, Blaha M, Lanska M, Gasova Z, Hrdlickova R, Ramlow W, Propheth H, Liumbruno G, Mori E, Griskevicius A, Audzijoniene J, Vrielink H, Rombout S, Aandahl A, Sikole A, Tomaz J, Lalic K Mazic S, Strineholm V, Brink B, Berlin G, Dykes J, Toss F, Axelsson CG, Stegmayr B, Nilsson T, Norda R, Knutson F, Ramsauer B, Wahlström A. Adverse events in apheresis: an update of the WAA registry data.Transfus Apher Sci 2016; 54: 2-15. Go to original source... Go to PubMed...
    26. Okamiya S, Ogino M, Ogino Y, Irie S, Kanazawa N, Saito T, Sakai F. Tryptophan-immobilized column-based immunoadsorption as the choicemethod for plasmapheresis in Guillain-Barré syndrome. Ther Apher Dial 2004; 8: 248-253. Go to original source... Go to PubMed...
    27. Palm M, Behm E, Schmitt E, Buddenhagen F, Hitzschke B, Kracht M, Kundt G, Meyer-Rienecker H, Klinkmann H. Immunoadsorption and plasma exchange in multiple sclerosis: complement and plasma protein behaviour. Biomater Artif Cells Immobilization Biotechnol. 1991; 19(1): 283-296. Go to original source... Go to PubMed...
    28. Pinching AJ, Peters DK. Remission of myasthenia gravis following plasma-exchange. Lancet 1976; 2: 1373-1376. Go to original source... Go to PubMed...
    29. Sauter M, Bender A, Heller F, Sitter T. A case report of the efficient reduction of calcium channel antibodies by tryptophan ligand immunoadsorption in a patient with Lambert-Eaton syndrome. Ther Apher Dial. 2010; 14(3): 364-367. Go to original source... Go to PubMed...
    30. Seta T, Nagayama H, Katsura K, Hamamoto M, Araki T, Yokochi M, Utsumi K, Katayama Y. Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg. 2005; 107(6): 491-496. Go to original source... Go to PubMed...
    31. Schimrigk S, Faiss J, Köhler W, Günther A, Harms L, Kraft A, Ehrlich S, Eberl A, Fassbender C, Klingel R, Galle J, Riedlinger A, Hoffmann F. Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunoadsorption - observational multicenter study with 147 patients. Eur Neurol. 2016; 75(5-6): 300-306. Go to original source... Go to PubMed...
    32. Schneider-Gold C, Krenzer M, Klinker E, Mansouri-Thalegani B, Müllges W, Toyka KV, Gold R. Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration. Ther Adv Neurol Disord. 2016; 9(4): 297-303. Go to original source... Go to PubMed...
    33. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the seventh special issue. J Clin Apher 2016; 31: 149-162). Go to original source... Go to PubMed...
    34. Takei H, Komaba Y, Araki T, Iino Y, Katayama Y. Plasma immunoadsorption therapy for Guillain-Barré syndrome: critical day for initiation. J Nippon Med Sch 2002; 69: 557-563. Go to original source... Go to PubMed...
    35. Willison HJ, Townson K, Veitch J, Boffey J, Isaacs N, Andersen SM, Zhang P, Ling CC, Bundle DR. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. Brain 2004; 127: 680-691. Go to original source... Go to PubMed...
    36. Yamada C, Teener JW, Davenport RD, Cooling L. Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients. J Clin Apher. 2015; 30(5): 314-39. Go to original source... Go to PubMed...
    37. Yamazaki Z, Idezuki Y, Inoue N, Yoshizawa H, Yamawaki N, Inagaki K, Tsuda N. Extracorporeal immunoadsorption with IM-PH or IM-TR column. Biomater Artif Cells Artif Organs 1989; 17: 117-124. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.